CTEV — Claritev Corporation stock price, charts and financials

QT63Claritev Corporation

Claritev Corporation (NYSE: CTEV) is a Healthcare company in the Medical - Healthcare Information Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
34.87
+2.28+7.00%
CTEVQT63Claritev Corporation·NYSE
34.87+7.00%
Earnings
Up 7.0% — Reported earnings — EPS missed by 8%, revenue beat by 4%.
High confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E-EPS (ttm)-17.33Insider Own23.65%Shs Outstand17.05MPerf Week43.51%
Market Cap555.59MForward P/E-EPS next Y-13.87Insider Trans2.41%Shs Float7.28MPerf Month-0.94%
Enterprise Value5.16BPEG-EPS next Q-Inst Own-Short Float5.79%Perf Quarter34.61%
Income-286.74MP/S0.56EPS this Y8.09%Inst Trans-Short Ratio6.74Perf Half Y26.81%
Sales994.68MP/B-EPS next Y12.89%ROA-5.94%Short Interest986.97KPerf YTD-23.77%
Book/sh-P/C4.12EPS next 5Y-ROE139.56%52W High79.25 -56.00%Perf Year-36.27%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC1.06%52W Low12.30 183.39%Perf 3Y-
Dividend Est.-EV/EBITDA15.24Sales past 3/5Y-3.68% 0.57%Gross Margin35.43%Volatility13.91% 10.08%Perf 5Y-
Dividend TTM-EV/Sales5.19EPS Y/Y TTM83.00%Oper. Margin4.90%ATR (14)3.07Perf 10Y-
Dividend Ex-Date-Quick Ratio1.00Sales Y/Y TTM5.26%Profit Margin-28.46%RSI (14)64.55Recom2.17
Dividend Gr. 3/5Y-Current Ratio1.00EPS Q/Q-28.57%SMA2023.47%Beta2.19Target Price38.80
Payout0.00%Debt/Eq-Sales Q/Q6.06%SMA5013.80%Rel Volume2.16Prev Close32.59
Employees3,000LT Debt/Eq-27.62EarningsAug 07SMA2006.17%Avg Volume152.54KPrice34.87
IPO DateApr 03, 2020Option/ShortYes / YesEPS/Sales Surpr.-7.94% 3.51%Net Debt/EBITDA13.60Volume329,967Change7.00%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-21-26ReiteratedCanaccord GenuityBuy$37
Jun-03-26ReiteratedPiper SandlerOverweight$90$61
Apr-24-26InitiatedBarclaysOverweight$28
Feb-24-26ReiteratedGuggenheimBuy$38
Feb-24-26ReiteratedWells FargoEqual Weight$33$30
Jan-08-26InitiatedWells FargoEqual Weight$33
Oct-22-25UpgradeCitigroupNeutralBuy
Oct-21-25UpgradeCitigroupNeutralBuy
May-29-25UpgradePiper SandlerNeutralOverweight
Latest News
Aug-07-26
Aug-07-2611:04PM
Aug-04-26
Jul-30-26
Jul-28-26
Jul-21-26
Jul-16-26
Jul-14-26
Jul-09-26
Jun-22-26
Jun-17-26
Company

Claritev Corporation, together with its affiliated companies, provides advanced data analytics and technology-enabled services focused on cost management, payment optimization, and revenue assurance for the healthcare sector across the United States. The company offers a suite of services designed to reduce medical expenses. This includes analytics-driven solutions that utilize sophisticated algorithms and data insights to pinpoint billing overcharges, subsequently assisting with or recommending appropriate reimbursement negotiations. Additionally, their network-focused services secure discounted rates through contracts with healthcare providers and provide outsourced administration for these provider networks. Claritev also specializes in payment and revenue integrity, identifying and removing erroneous or unwarranted charges processed during claims, while simultaneously working to identify, recover, and safeguard underpaid premium amounts. Furthermore, their data and decision science offerings encompass a range of solutions that apply modern data science methodologies—including descriptive, predictive, and prescriptive analytics—to refine benefit plan structures, aid strategic decision-making, enhance patient clinical results, and ultimately lower overall healthcare costs. The company also handles business-to-business healthcare payment processing and other related services. Their diverse clientele includes major national and regional insurance carriers, Blue Cross and Blue Shield organizations, various provider-sponsored and independent health plans, third-party administrators (TPAs), self-insured health plans, property and casualty insurers, bill review firms, and other entities involved in the claims settlement process. Established in 1980 and headquartered in New York, New York, Claritev Corporation was previously known as MultiPlan Corporation before officially adopting its current name in February 2025.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue995965931
Cost of Goods Sold Incl. D&A500699239
Gross Profit353267691
Selling, General and Administrative Excl. Other209222160
Research and Development
000
Other Operating Expense23801,921
Operating Income4945-1,390
Interest Expense400400326
Unusual Expense
Non-Operating Income (Expense)46-18-54
Net Income Before Taxes-305-373-1,771
Income Taxes-2-89-125
Consolidated Net Income-284-284-1,646
Net Income From Continuing Operations-225-284-1,646
Net Income-284-284-1,646
EPS (Recurring)-17.00-17.30-101.92
EPS (Basic, Before Extraordinaries)-17.00-17.30-101.92
EPS (Diluted)-17.00-17.30-101.92
EBITDA339475-1,008
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio
Price To Sales Ratio0.600.71
Gross Margin35.4827.6774.22
Operating Margin4.924.66-149.30
Net Margin-28.54-29.43-176.80
Shares Outstanding171616
Market Capitalization593684
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$81.45$62.24$43.02$23.81$4.60 Close Price0.00M18.25M36.50M54.75M73.00MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Carol NutterSVP, Chief People OfficerJun 09 '26Buy28.4187524,85646,941Jun 10
Prince John MichaelDirectorMay 19 '26Buy16.0010,000160,00031,662May 19
Dalton TravisPres., CEO & Executive ChairMay 18 '26Buy12.3620,920258,63845,872May 19
Kim MichaelEVP, Chief Digital OfficerMay 18 '26Buy16.653,00049,950185,878May 19
Garis Douglas MichaelEVP&CFOMar 16 '26Buy17.691,30022,997206,152Mar 16
Kim MichaelEVP, Chief Digital OfficerMar 12 '26Buy16.5015,000247,500182,878Mar 16
O'Neil TaraSVP, General CounselMar 02 '26Buy12.997509,74327,199Mar 02
Dalton TravisPres., CEO & Executive ChairFeb 27 '26Buy13.0015,380199,92824,952Mar 02
Kim MichaelEVP, Chief Digital OfficerFeb 27 '26Buy14.3030,000428,955137,973Mar 02
Dalton TravisPres., CEO & Executive ChairNov 20 '25Buy47.235,290249,8429,572Nov 20
Mintz William B.SVP, Chief Strategy OfficerNov 17 '25Buy38.0091634,80865,325Nov 19
Kim MichaelEVP, Chief Digital OfficerNov 17 '25Buy38.259,600367,199105,529Nov 18
O'Neil TaraSVP, General CounselNov 17 '25Buy38.8462524,27325,028Nov 18
H&F Corporate Investors VIII, Ltd.10% OwnerNov 12 '25Sale48.671,500,00073,001,2498,932Nov 14
Dalton TravisPres., CEO & Executive ChairAug 11 '25Buy58.303,982232,1584,282Aug 12
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.